MYRIAD GENETICS INC

Myriad Genetics (MYGN) climbs 43.6% YTM, trading near its 52‑week high with strong liquidity and a lower price than peers – a promising entry for precision‑medicine investors.

Myriad Genetics stock slides to $5.69, showing minimal growth amid a rising Nasdaq. With a low market cap and no new earnings, investors must weigh cautious risk.

Myriad Genetics surges 31.6% after announcing a $210 M sale of its prenatal unit to Labcorp, sharpening focus on high‑margin oncology and genomic diagnostics.